Xeris Biopharma Holdings develops and commercializes therapies for patients with endocrinology, neurology, and gastroenterology conditions. They sell Gvoke for severe hypoglycemia, Keveyis for various forms of periodic paralysis, and Recorlev for endogenous hypercortisolemia. Xeris has additional products in development and uses their proprietary formulation technology platforms, XeriSol and XeriJect, to bring new products to the market.